http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009124764-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_049084b4dec6597da3f384997c47432e http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_118a8f9a778b514a4c3bbcbee12a8b67 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cdbc1f98b67a6274b5d5033fdd736eab http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fc636834f69d4b9da1e14a5a03d5a4bb |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D257-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0482 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0491 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D257-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D257-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D257-02 |
| filingDate | 2009-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_23b82c16a3a2b9209da9c9533714d174 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4464fbfa36b9b7bd376b41a5f15a7272 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_99619b96cb044d265214f273280b6cb3 |
| publicationDate | 2009-10-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2009124764-A1 |
| titleOfInvention | Compound composed of a metal ion and a marker precursor having two or more targeting vectors, and use of the compound |
| abstract | The invention relates to a compound composed of a metal ion, or metal, such as a radiopharmaceutical from a metal radio-nuclide, and a marker precursor, which is constructed of a bi-functional, macrocyclic chelator, a spacer, a linker, and at least two targeting vectors. For this purpose, the chelator comprises preferably a 9-, 10-, 11-, 12-, 14-, or 16-link polyazamacrocycle, preferably further complexing donors. The spacer is preferably constructed of linear, branched, or hetero-substituted, saturated, unsaturated, or aromatic hydrocarbons, or of sugars. Targeting vectors are preferably proteinogenic or synthetic a-amino-carboxylic acids. The metal radio-nuclides are preferably 2-, 3-, or 4-valent, wherein the gallium radio-isotopes 65Ga, 66Ga, 67Ga, 68Ga, 70Ga, and 72Ga are preferred. The radiopharmaceutical is suitable for the nuclear medical diagnosis of tumors by means of positron emission tomography (PET), and by means of single photon emission computer tomography (SPECT). In endo-radiotherapy (ERT) the radiopharmaceutical is incorporated directly or systemically into the target tissue. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10093741-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022194298-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11191854-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11433148-B2 |
| priorityDate | 2008-04-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 45.